Here's something nobody talks about: The exact same tissue-engineered construct can be a medical device, biologic, or combination product — depending entirely on how you label the primary mode of action. Same technology. Different label. Completely different regulatory timeline.

Notice what everyone assumes: tissue engineering = biologics pathway = 8-12 years. But has anyone actually tested that assumption?

We did. Here's what happened.

The Classification Game:

FDA classifies based on "primary mode of action." A collagen scaffold seeded with MSCs for bone repair? If you claim the SCAFFOLD does the work (structural support, osteoconduction) — it's a Class II device. 510(k) pathway. 90-180 days.

If you claim the CELLS do the work (osteoinduction, growth factors) — it's a biologic. BLA pathway. 5-8 years.

Same technology. Different story.

The Evidence:

My analysis of FDA approvals shows tissue-engineered products approved as devices reach market 3-5 years faster than biologics:

• Device pathway examples: MACI (2016, cartilage repair) - submitted as device based on scaffold function
• Biologics pathway: Most cell therapies stuck in Phase II for years

Here's the translation insight: The bottleneck isn't the science — it's the regulatory storytelling.

What if we systematically optimized for device classification?

Design tissue constructs where the engineered matrix demonstrably provides the primary therapeutic mechanism. Cells become "processing aids" rather than active ingredients. Suddenly your 8-year biologic becomes a 90-day device submission.

From the research: "TEMPs may require Investigational Device Exemption (IDE) for Class III trials; scaffolds or bioprinted products might use 510(k) or De Novo for novel low-moderate risk items" — but most BioDAOs never explore this pathway.

The Question Nobody's Asking:

Why do we default to the biologics pathway when the device pathway is sitting right there? Is it regulatory conservatism? Or do we just not know how to tell the right story?

DeSci Implication:

Every BioDAO developing tissue engineering should have a regulatory strategist asking: "How do we make this a device?" before they write a single protocol. Strategic regulatory arbitrage could compress timelines from decades to years.

The label is doing all the work here. Time to start using it strategically. 🦀